The Effectiveness of Anti-Nerve Growth Factor Monoclonal Antibodies in the Management of Pain in Osteoarthritis of the Hip and Knee: A PRISMA Systematic Review and Meta-Analysis.

Abstract

OBJECTIVE:

To conduct a systematic review and meta-analysis of the efficacy of anti-nerve growth factor (NGF) monoclonal antibodies in osteoarthritis pain (hip and knee).

DESIGN:

Grade the evidence for anti-NGF use.

METHODS:

An interdisciplinary work group conducted a literature search for anti-NGF use in osteoarthritis. The systematic review was performed in accordance with methods described by the Cochrane collaboration. General inclusion criteria included all osteoarthritis trials studying any monoclonal anti-NGF antibody at any dose/phase. Excluded studies were those where participants received NSAIDs or analgesics other than anti-NGF antibodies. The Jadad Scale score was used to assess the quality of the included studies.

RESULTS:

Thirteen studies were included in the analysis, involving 8145 participants with a diagnosis of hip and/or knee osteoarthritis. Anti-NGF antibody treatment was associated with a significant improvement in all Western Ontario and McMaster Universities Arthritis Index (WOMAC) indices when compared to placebo. These agents were not associated with a significantly increased incidence of serious adverse events but were associated with significant increases in therapy discontinuation due to adverse events or side effects (e.g., peripheral neuropathy).

CONCLUSIONS:

Future randomized clinical trials are needed to characterize the overall risk-to-benefit ratio of anti-NGF antibodies in managing pain associated with OA, particularly with long-term use, in order to verify their efficacy and safety in clinical practice.

• Authors: K T Matthew Seah, Jashmitha Rammanohar, James Sutton, Kendrick To, Wasim S Khan
• Journal: Pain medicine (Malden, Mass.) (Pain Med) Vol. 22 Issue 5 Pg. 1185-1204 (05 21 2021) ISSN: 1526-4637 [Electronic] England
• PMID: 33616179 (Publication Type: Journal Article, Meta-Analysis, Systematic Review)
• Copyright: © The Author(s) 2021. Published by Oxford University Press on behalf of the American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: [email protected].

Chemical References

• Antibodies, Monoclonal
• Nerve Growth Factor

Topics

• Antibodies, Monoclonal (therapeutic use)
• Humans
• Nerve Growth Factor
• Ontario
• Osteoarthritis, Hip
• Osteoarthritis, Knee (drug therapy)
• Pain
• Pain Measurement
• Treatment Outcome